{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/8cf4cec7-5a0f-49c5-8ec9-36941b5c6b6e/657375835d8877001267c950?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Apeiron’s Christian Angermayer: “AI, psychedelics and living for hundreds of years” ","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61ba0b311a8cbef1d93cf121/1727779701141-224fba2b-4a29-49b2-8d7c-e6f0f25b0e74.jpeg?height=200","description":"<p>The Sunday Times' tech correspondent Danny Fortson brings on Christian Angermayer, founder of Apeiron Investments, to talk about psychedelics in Oregon (4:15), the spiritual experience of a “trip” (11:30),&nbsp;progressing toward the first FDA approval (15:30), how this will be introduced into the market (21:10), why having a qualified guide/therapist is critical (25:30), gaining societal acceptance (30:20), why he funded the longevity XPrize (34:20), the new approach to ageing (41:00), why we are on the cusp of a breakthrough in life span (42:30), the Ozempic effect (49:00, thriving in a toxic society (56:20), and how AI dovetails with psychedelics and longevity (1:01:50).</p>","author_name":"The Sunday Times"}